Efficacy and Safety of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Chronic Migraine
Status:
Completed
Trial end date:
2019-11-30
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy and safety of subcutaneous (SC) administration of TEV-48125 [monthly
TEV-48125 225 mg (loading dose only: 675 mg) and TEV-48125 675 mg once over a period of 3
months] compared with placebo for preventive treatment in Chronic Migraine patients